Muramatsu T - Search Results

1

In vivo gene transfer of endo-beta-galactosidase C removes alphaGal antigen on erythrocytes and endothelial cells of the organs.

Miki Y, Maruyama S, Liu D, Kobayashi T, Sato F, Shimizu H, Kato S, Sato W, Morita Y, Yuzawa Y, Muramatsu T, Matsuo S. Miki Y, et al. Among authors: muramatsu t. Xenotransplantation. 2004 Sep;11(5):444-51. doi: 10.1111/j.1399-3089.2004.00163.x. Xenotransplantation. 2004. PMID: 15303981

2

Enzymatic removal of alphaGal antigen in pig kidneys by ex vivo and in vivo administration of endo-beta-galactosidase C.

Liu D, Kobayashi T, Yokoyama I, Ogawa H, Nagasaka T, Muramatsu H, Kadomatsu K, Oikawa T, Shimano Y, Morozumi K, Uchida K, Muramatsu T, Nakao A. Liu D, et al. Among authors: muramatsu h, muramatsu t. Xenotransplantation. 2002 May;9(3):228-36. doi: 10.1034/j.1399-3089.2002.01068.x. Xenotransplantation. 2002. PMID: 11983021

3

Reduction of alpha-galactosyl xenoantigen by expression of endo-beta-galactosidase C in pig endothelial cells.

Ogawa H, Kobayashi T, Yokoyama I, Nagatani N, Mizuno M, Yoshida J, Kadomatsu K, Muramatsu H, Nakao A, Muramatsu T. Ogawa H, et al. Among authors: muramatsu h, muramatsu t. Xenotransplantation. 2002 Jul;9(4):290-6. doi: 10.1034/j.1399-3089.2002.01098.x. Xenotransplantation. 2002. PMID: 12060465

4

Midkine antisense oligodeoxyribonucleotide inhibits renal damage induced by ischemic reperfusion.

Sato W, Takei Y, Yuzawa Y, Matsuo S, Kadomatsu K, Muramatsu T. Sato W, et al. Among authors: muramatsu t. Kidney Int. 2005 Apr;67(4):1330-9. doi: 10.1111/j.1523-1755.2005.00210.x. Kidney Int. 2005. PMID: 15780085 Free article.

5

Midkine expression in the course of nephrogenesis and its role in ischaemic reperfusion injury.

Sato W, Yuzawa Y, Kadomatsu K, Tayasu T, Muramatsu H, Muramatsu T, Matsuo S. Sato W, et al. Among authors: muramatsu h, muramatsu t. Nephrol Dial Transplant. 2002;17 Suppl 9:52-4. doi: 10.1093/ndt/17.suppl_9.52. Nephrol Dial Transplant. 2002. PMID: 12386288

6

A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics.

Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. Takei Y, et al. Among authors: muramatsu t. Cancer Res. 2004 May 15;64(10):3365-70. doi: 10.1158/0008-5472.CAN-03-2682. Cancer Res. 2004. PMID: 15150085

7

Lack of the growth factor midkine enhances survival against cisplatin-induced renal damage.

Kawai H, Sato W, Yuzawa Y, Kosugi T, Matsuo S, Takei Y, Kadomatsu K, Muramatsu T. Kawai H, et al. Among authors: muramatsu t. Am J Pathol. 2004 Nov;165(5):1603-12. doi: 10.1016/S0002-9440(10)63417-7. Am J Pathol. 2004. PMID: 15509530 Free PMC article.

8

Growth factor midkine is involved in the pathogenesis of diabetic nephropathy.

Kosugi T, Yuzawa Y, Sato W, Kawai H, Matsuo S, Takei Y, Muramatsu T, Kadomatsu K. Kosugi T, et al. Among authors: muramatsu t. Am J Pathol. 2006 Jan;168(1):9-19. doi: 10.2353/ajpath.2006.050488. Am J Pathol. 2006. PMID: 16400005 Free PMC article.

9

In vivo silencing of a molecular target by short interfering RNA electroporation: tumor vascularization correlates to delivery efficiency.

Takei Y, Nemoto T, Mu P, Fujishima T, Ishimoto T, Hayakawa Y, Yuzawa Y, Matsuo S, Muramatsu T, Kadomatsu K. Takei Y, et al. Among authors: muramatsu t. Mol Cancer Ther. 2008 Jan;7(1):211-21. doi: 10.1158/1535-7163.MCT-07-0319. Mol Cancer Ther. 2008. PMID: 18202023

10

Morpholino antisense oligomer targeting human midkine: its application for cancer therapy.

Takei Y, Kadomatsu K, Yuasa K, Sato W, Muramatsu T. Takei Y, et al. Among authors: muramatsu t. Int J Cancer. 2005 Apr 10;114(3):490-7. doi: 10.1002/ijc.20781. Int J Cancer. 2005. PMID: 15578698

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,734 results

Search Page

Filters